Akebia Therapeutics Prices Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- McKesson reports cybersecurity incident affecting its information systems
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- BioNTech ends colorectal cancer mRNA therapy trial early
Akebia Therapeutics (AKBA) Moves into Oversold Territory Following Equity Offering
April 17, 2015 3:54 PM EDTAkebia Therapeutics (Nasdaq: AKBA) is notably lower Friday after pricing a 7,272,727 share common stock offering at $8.25 each. But, investors might do well to keep an eye on the name.
The 14-day money flow index is at 10.6 percent, which is well below the 20 percent... More
Akebia Therapeutics (AKBA) Prices 7.27M Common Offering at $8.25/Share
April 17, 2015 6:10 AM EDTAkebia Therapeutics (NASDAQ: AKBA) announced the pricing of an underwritten public offering of 7,272,727 shares of common stock at a price to the public of $8.25 per share. The net proceeds of the offering are expected to be approximately $56.1 million, after deducting underwriting discounts and commissions and... More
